Guest Blog|Real world evidence – the art of the possible

DATA-CAN’s scientific lead, Professor Mark Lawler, presented at the BioIndustry Association UK Bioscience Forum on the use of Real World Evidence in helping to transform cancer services.

Hikma and Arecor Expand Collaboration with New Agreement to Develop and Commercialise Ready-To-Administer Medicine

Hikma and Arecor today announce they have entered into a new exclusive agreement to co-develop a ready-to-administer injectable medicine in the US through Hikma’s affiliate, Hikma Pharmaceuticals USA Inc. The agreement builds on Hikma and Arecor’s first product co-development agreement, which was announced on 9 January 2020.

Arcinova announces major investment in Alnwick site with the installation of the R1000 capsule fill machine from 3P Innovation

Arcinova, a multi-service Contract Development and Manufacturing Organisation (CDMO) based in Alnwick, Northumberland, has recently taken delivery and commissioned the award winning R1000 Robotic Capsule Filler from life-sciences automation company 3P innovation, as part of the ‘Fill-Inova’ project.

CEO Update|Monday 19 October

It’s our Annual General Meeting this week which you can join on Zoom and I’m expecting a big week for Brexit. Thank you to members who stood for and voted in our Board election in recent weeks. The results will be announced at our first virtual AGM this Wednesday and I invite all members to join. For the full meeting details and password, please email Nick Gardiner He will also be circulating these details to all main members shortly.

Fieldfisher advises Synairgen plc on fundraising of up to £87 million to support Phase III trials of its potential COVID-19 treatment

European law firm Fieldfisher has advised AIM-quoted Synairgen plc, a leading respiratory disease drug discovery company based in Southampton, on its £87 million fundraising to begin the Phase III trial for a potential inhaled treatment for COVID-19

Iksuda Therapeutics enters license agreement with University of Goettingen to develop a new generation of antibody drug conjugates

• Iksuda licenses novel protein-alkylating, tumour-activated pro-drug payload series to develop ADCs with enhanced therapeutic index • Development to focus on targets associated with haematological and solid tumours

Record quarter for UK biotech as £1bn is raised

New data published today by the BioIndustry Association (BIA) and Clarivate reveals that UK biotech companies raised more than £1billion in equity finance between June and August 2020, the highest quarter for investments in the sector on record.

CEO Update|Monday 12 October

The BIA’s latest investment report shows a record quarter for investment in the UK biotech sector, Nobel prizes and Honours for the sector, plus Tony Blair joins us for a keynote session at our flagship autumn conference, the UK Bioscience Forum.

Oncimmune and Medicines Discovery Catapult awarded UK Government funding for development of an Infectious Disease research tool for use in COVID-19

Validated research tool to be used to predict disease severity and individual therapeutic response to COVID-19 in aid of rapid vaccine and drug development

CEO Update|Monday 05 October

The BIA’s UK Bioscience Forum takes place next week 14-15 October and will focus on the opportunities and challenges of Emerging Data Technologies in the life sciences. The full programme is available here featuring speakers from IQVIA, NICE, Benevolent AI, Lifebit, Babylon, AWS, Deepmatter, Closed Loop Medicine, Mogrify, Elsevier, Stratagem IPM, Microsoft, Illumina, Novartis Biome, Milner Therapeutics Institute, Oxford Nanopore, UK Biobank, IBM, Sensyne and UKRI amongst others.